Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.

To describe prostate-specific antigen (PSA) response and treatment adherence, overall and stratified by race, for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide.

Electronic medical records representing 63 urology practices from the US were used to conduct this study. Patients with ≥2 apalutamide prescription fills and ≥12 months of prior prostate cancer management were identified. Patients were followed from apalutamide initiation until a switch to another antineoplastic treatment, death, or end of data availability (10/04/2019). PSA response (≥50% decline from baseline PSA) and apalutamide adherence rates are described for the overall nmCRPC population treated and also stratified by race (Black and non-Black cohorts).

Overall, 193 patients with nmCRPC were initiated on apalutamide. Thirty-three patients were Black (17.1%), 138 were non-Black (71.5%), and the remaining had an unknown racial background. The mean baseline PSA level for the overall, Black, and non-Black cohorts, was 7.0 ng/mL, 10.5 ng/mL, and 5.6 ng/mL, respectively. At 12 months of follow-up, PSA response was 86.0%, 93.1%, and 85.9% for the overall, Black, and non-Black cohorts among, respectively. During a mean follow-up period of 333 days, 352 days, and 326 days, adherence was 93.6%, 90.1%, and 94.5% for the overall, Black and non-Black cohorts, respectively.

This real-world study of patients with nmCRPC initiated on apalutamide showed that PSA response was robust and consistent with clinical trial data. Moreover, both Black and non-Black patients demonstrated high treatment adherence.

Urology. 2022 Mar 19 [Epub ahead of print]

Benjamin Lowentritt, Gordon Brown, Dominic Pilon, Lorie Ellis, Guillaume Germain, Carmine Rossi, Patrick Lefebvre, Kenneth Kernen, Paul Sieber, Neal Shore

Chesapeake Urology, 8322 Bellona Avenue, Towson, Maryland 21204, USA., New Jersey Urology, 2090 Springdale Road, Cherry Hill, New Jersey 08003, USA., Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Deloitte Tower, Suite 1500 Montréal, Quebec, H3B 0G7, Canada. Electronic address: ., Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, Pennsylvania 19044, USA., Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Deloitte Tower, Suite 1500 Montréal, Quebec, H3B 0G7, Canada., Michigan Institute of Urology, 6900 Orchard Lake Road, West Bloomfield, Michigan 48322, USA., Keystone Urology, 2106 Harrisburg Pike, Lancaster, Pennsylvania 17601, USA., Carolina Urologic Research Center, 823 82nd Pkwy, Myrtle Beach, South Carolina 29572, USA.

Go Beyond the Abstract and Read a Commentary by the Author